Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK F1174L NRAS Q61K |
| Therapy | Ceritinib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK F1174L NRAS Q61K | neuroblastoma | resistant | Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of NRAS Q61K in a neuroblastoma cell line harboring ALK F1174L conferred resistance to Zykadia (ceritinib) in culture (PMID: 35689207). | 35689207 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35689207) | Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. | Full reference... |